|Trade names||Dogmatil, others|
|AHFS/Drugs.com||International Drug Names|
|By mouth (tablets, capsules, solution), intramuscular injection|
|Elimination half-life||6–8 hours|
Feces (~95% as the unchanged drug)
|CompTox Dashboard (EPA)|
|Chemical and physical data|
|Molar mass||341.43 g·mol−1|
|3D model (JSmol)|
Sulpiride, sold under the brand name Dogmatil among others, is an atypical antipsychotic (although some texts have referred to it as a typical antipsychotic) medication of the benzamide class which is used mainly in the treatment of psychosis associated with schizophrenia and major depressive disorder, and sometimes used in low dosage to treat anxiety and mild depression. Sulpiride is commonly used in Asia, Central America, Europe, South Africa and South America. Levosulpiride is its purified levo-isomer and is sold in India for similar purpose. It is not approved in the United States, Canada, or Australia. The drug is chemically and clinically similar to amisulpride.
Sulpiride's primary use in medicine is in the management of the symptoms of schizophrenia. It has been used as both a monotherapy and adjunctive therapy (in case of treatment-resistance) in schizophrenia. It has also been used in the treatment of dysthymia. There is evidence, although low quality, that Sulpiride could accelerate antidepressant response in patients with major depressive disorder. There is also evidence of its efficacy in treating panic disorder. Sulpiride is indicated for the treatment of vertigo in some countries. In Japan, Sulpiride is both approved as a treatment for schizophrenia and for major depressive disorder (low dose).
- Hypersensitivity to sulpiride
- Pre-existing breast cancer or other prolactin-dependent tumors
- Intoxication with other centrally-active drugs
- Concomitant use of levodopa
- Acute porphyria
- Comatose state or CNS depression
- Bone-marrow suppression
- Pre-existing Parkinson's disease
- Patients under 18 years of age (insufficient clinical data)
- Pre-existing severe heart disease/bradycardia, or hypokalemia (predisposing to long QT syndrome and severe arrhythmias)
- Patients with pre-existing epilepsy. Anticonvulsant therapy should be maintained
- Lithium use — increased risk of neurological side effects of both drugs
Pregnancy and lactation
- Pregnancy: Animal studies did not reveal any embryotoxicity or fetotoxicity, nor did limited human experience. Due to insufficient human data, pregnant women should be treated with sulpiride only if strictly indicated. Additionally, the newborns of treated women should be monitored, because isolated cases of extrapyramidal side effects have been reported.
- Lactation: Sulpiride is found in the milk of lactating women. Since the consequences are unclear, women should not breastfeed during treatment.
- Common (>1%) adverse effects
- Extrapyramidal side effects
- - Tremor
- - Dystonia
- - Akathisia — a sense of inner restlessness that presents itself with the inability to stay still
- - Parkinsonism
- Somnolence (not a very prominent adverse effect considering its lack of α1 adrenergic, histamine and muscarinic acetylcholine receptor affinity)
- Weight gain or loss
- Hyperprolactinemia (elevated plasma levels of the hormone, prolactin which can, in turn lead to sexual dysfunction, galactorrhea, amenorrhea, gynecomastia, etc.)
- Nasal congestion
- Anticholinergic adverse effects such as:
- - Dry mouth
- - Constipation
- - Blurred vision
- Impaired concentration
- Rare (<1% incidence) adverse effects
- Tardive dyskinesia — a rare, often permanent movement disorder that, more often than not, results from prolonged treatment with antidopaminergic agents such as antipsychotics. It presents with slow (hence tardive), involuntary, repetitive and purposeless movements that most often affect the facial muscles.
- Neuroleptic malignant syndrome — a rare, life-threatening complication that results from the use of antidopaminergic agents. Its incidence increases with concomitant use of lithium (medication) salts
- Blood dyscrasias — rare, sometimes life-threatening complications of the use of a number of different antipsychotics (most notably clozapine) which involves abnormalities in the composition of a person's blood (e.g. having too few white blood cells per unit volume of blood). Examples include:
- - Agranulocytosis — a significant drop in white blood cell count, leaving individuals wide open to life-threatening opportunistic infections
- - Neutropenia
- - Leucopenia
- - Leukocytosis
- Torsades de pointes
- Unknown incidence adverse effects include
- QTc interval prolongation which can lead to potentially fatal arrhythmias.
- Cholestatic jaundice
- Elevated liver enzymes
- Primary biliary cirrhosis
- Allergic reactions
- Photosensitivity — sensitivity to light
- Skin rashes
- Diaphoresis — sweating without a precipitating factor (e.g. increased ambient temperature)
- Hypotension — low blood pressure
- Hypertension — high blood pressure
- Venous thromboembolism (probably rare)
Sulpiride has a relatively low order of acute toxicity. Substantial amounts may cause severe but reversible dystonic crises with torticollis, protrusion of the tongue, and/or trismus. In some cases all the classical symptoms typical of severe Parkinson's disease may be noted; in others, over-sedation/coma may occur. The treatment is largely symptomatic. Some or all extrapyramidal reactions may respond to the application of anticholinergic drugs such as biperiden or benzatropine. All patients should be closely monitored for signs of long QT syndrome and severe arrhythmias.
Sulpiride neither inhibits nor stimulates cytochrome P450 family (CYP) of oxidizing enzymes in human, thus would not cause clinically significant interactions with other drugs, which are metabolized by CYPs. However, the risk or severity of adverse effects can be increased when sulpiride is combined with other drugs, but this is not related to substrates, inducers and inhibitors of CYPs.
|Receptor||Affinity (Ki, nM)|
|Affinity values are toward cloned human receptors.|
Sulpiride is a selective antagonist at dopamine D2, D3 and 5-HT1A receptors. Antagonism at 5-HT1A dominates in doses exceeding 600 mg daily. In doses of 600 to 1,600 mg sulpiride shows mild sedating and antipsychotic activity. Its antipsychotic potency compared to chlorpromazine is only 0.2 (1/5). In low doses (in particular 50 to 200 mg daily) its prominent feature is antagonism of presynaptic inhibitory dopamine and serotonin receptors, accounting for some antidepressant activity and a stimulating effect. Additionally, it alleviates vertigo.
The benzamide neuroleptics (including sulpiride, amisulpride, and sultopride) have been shown to activate the endogenous gamma-hydroxybutyrate receptor in vivo at therapeutic concentrations. Sulpiride was found in one study in rats to upregulate GHB receptors. GHB has neuroleptic properties and it is believed binding to this receptor may contribute to the effects of these neuroleptics.
Sulpiride can be synthesized from 5-aminosulfosalicylic acid. Methylating this with dimethylsulfate gives 2-methoxy-5-aminosulfonylbenzoic acid, which is transformed into an amide using 2-aminomethyl-1-ethylpyrrolidine as the amine component and carbonyldiimidazole (CDI) as a condensing agent.
Sulpiride was discovered as a result of a research program by Justin-Besançon and C. Laville at Laboratoires Delagrange who were working to improve the anti-dysrhythmic properties of procainamide; the program led first to metoclopramide and later to sulpiride. Laboratoires Delagrange was acquired by Synthelabo in 1991 which eventually became part of Sanofi.
Society and culture
These include tablet and oral solution
Sulpiride has been studied for use as a hormonal contraceptive in women in whom conventional oral contraceptives are contraindicated and to potentiate progestogen-only contraceptives. The contraceptive effects of sulpiride are due to its prolactin-releasing and antigonadotropic effects and the hyperprolactinemia–amenorrhea state that it induces.
- "Sulpiride Tablets 200mg, 400mg (SPC)". electronic Medicines Compendium (eMC). Sanofi. 21 January 2010. Archived from the original on 19 October 2013. Retrieved 19 October 2013.
- Bressolle F, Brès J, Fauré-Jeantis A (January 1992). "Absolute bioavailability, rate of absorption, and dose proportionality of sulpiride in humans". Journal of Pharmaceutical Sciences. 81 (1): 26–32. doi:10.1002/jps.2600810106. PMID 1619566.
- Imondi AR, Alam AS, Brennan JJ, Hagerman LM (March 1978). "Metabolism of sulpiride in man and rhesus monkeys". Archives Internationales de Pharmacodynamie et de Therapie. 232 (1): 79–91. PMID 96745.
- Niwa, T.; Inoue, S.; Shiraga, T.; Takagi, A. (2005). "No Inhibition of Cytochrome P450 Activities in Human Liver Microsomes by Sulpiride, an Antipsychotic Drug". Biological & Pharmaceutical Bulletin. 28 (1): 188–91. doi:10.1248/bpb.28.188. PMID 15635191.
- Telles-Correia, D.; Barbosa, A.; Cortez-Pinto, H.; Campos, C.; Rocha, N. B.; Machado, S. (2017). "Psychotropic Drugs and Liver Disease: A Critical Review of Pharmacokinetics and Liver Toxicity". World Journal of Gastrointestinal Pharmacology and Therapeutics. 8 (1): 26–38. doi:10.4292/wjgpt.v8.i1.26. PMC 5292604. PMID 28217372.
- Lv, Q.; Yi, Z. (2018). "Antipsychotic Drugs and Liver Injury". Shanghai Archives of Psychiatry. 30 (1): 47–51. PMC 5925599. PMID 29719358.
- Kobari, T.; Namekawa, H.; Kato, Y.; Yamada, S. (1985). "Biotransformation of Sultopride in Man and Several Animal Species". Xenobiotica; the Fate of Foreign Compounds in Biological Systems. 15 (6): 469–76. doi:10.3109/00498258509045020. PMID 4036171.
- Joint Formulary Committee (2013). British National Formulary (BNF) (65 ed.). London, UK: Pharmaceutical Press. ISBN 978-0-85711-084-8.
- Taylor D, Paton C, Shitij K (2012). The Maudsley prescribing guidelines in psychiatry. West Sussex: Wiley-Blackwell. ISBN 978-0-470-97948-8.
- Wang J, Omori IM, Fenton M, Soares B (January 2010). "Sulpiride augmentation for schizophrenia". The Cochrane Database of Systematic Reviews (1): CD008125. doi:10.1002/14651858.CD008125.pub2. PMID 20091661.
- Lai EC, Chang CH, Kao Yang YH, Lin SJ, Lin CY (May 2013). "Effectiveness of sulpiride in adult patients with schizophrenia". Schizophrenia Bulletin. 39 (3): 673–83. doi:10.1093/schbul/sbs002. PMC 3627763. PMID 22315480.
- Soares BG, Fenton M, Chue P (2000). "Sulpiride for schizophrenia". The Cochrane Database of Systematic Reviews (2): CD001162. doi:10.1002/14651858.CD001162. PMID 10796605.
- Omori IM, Wang J, Soares B, Fenton M (October 2009). "Sulpiride versus other antipsychotics for schizophrenia (Protocol)". The Cochrane Database of Systematic Reviews (4): CD008126. doi:10.1002/14651858.CD008126.
- Pani L, Gessa GL (2002). "The substituted benzamides and their clinical potential on dysthymia and on the negative symptoms of schizophrenia". Molecular Psychiatry. 7 (3): 247–53. doi:10.1038/sj.mp.4001040. PMID 11920152.
- Uchida H, Takeuchi H, Suzuki T, Nomura K, Watanabe K, Kashima H (December 2005). "Combined treatment with sulpiride and paroxetine for accelerated response in patients with major depressive disorder". Journal of Clinical Psychopharmacology. 25 (6): 545–51. doi:10.1097/01.jcp.0000185425.00644.41. PMID 16282835. S2CID 10727911.
- Bell C, Bhikha S, Colhoun H, Carter F, Frampton C, Porter R (February 2013). "The response to sulpiride in social anxiety disorder: D2 receptor function". Journal of Psychopharmacology. 27 (2): 146–51. doi:10.1177/0269881112450778. PMID 22745189. S2CID 32951554.
- Nunes EA, Freire RC, Dos Reis M, de Oliveira E, Silva AC, Machado S, et al. (September 2012). "Sulpiride and refractory panic disorder". Psychopharmacology. 223 (2): 247–9. doi:10.1007/s00213-012-2818-6. PMID 22864966. S2CID 14870287.
- "Medicinanet - Equilid 50". Retrieved 5 September 2018.
- "Search results detail| Kusurino-Shiori(Drug information Sheet)". www.rad-ar.or.jp. Retrieved 16 March 2020.
- Towlson, Emma K.; Vértes, Petra E.; Müller-Sedgwick, Ulrich; Ahnert, Sebastian E. (12 September 2019). "Brain Networks Reveal the Effects of Antipsychotic Drugs on Schizophrenia Patients and Controls". Frontiers in Psychiatry. 10: 611. doi:10.3389/fpsyt.2019.00611. ISSN 1664-0640. PMC 6752631. PMID 31572229.
- Lepola U, Koskinen T, Rimón R, Salo H, Gordin A (July 1989). "Sulpiride and perphenazine in schizophrenia. A double-blind clinical trial". Acta Psychiatrica Scandinavica. 80 (1): 92–6. doi:10.1111/j.1600-0447.1989.tb01305.x. PMID 2669445. S2CID 28719315.
- Munk-Andersen E, Behnke K, Heltberg J, Nielsen H, Gerlach J (1984). "Sulpiride versus haloperidol, a clinical trial in schizophrenia. A preliminary report". Acta Psychiatrica Scandinavica. Supplementum. 311: 31–41. doi:10.1111/j.1600-0447.1984.tb06857.x. PMID 6367362. S2CID 31689174.
- Gerlach J, Behnke K, Heltberg J, Munk-Anderson E, Nielsen H (September 1985). "Sulpiride and haloperidol in schizophrenia: a double-blind cross-over study of therapeutic effect, side effects and plasma concentrations". The British Journal of Psychiatry. 147 (3): 283–8. doi:10.1192/bjp.147.3.283. PMID 3904885.
- Standish-Barry HM, Bouras N, Bridges PK, Watson JP (1983). "A randomized double blind group comparative study of sulpiride and amitriptyline in affective disorder". Psychopharmacology. 81 (3): 258–60. doi:10.1007/bf00427274. PMID 6417717. S2CID 28134446.
- Quinn N, Marsden CD (August 1984). "A double blind trial of sulpiride in Huntington's disease and tardive dyskinesia". Journal of Neurology, Neurosurgery, and Psychiatry. 47 (8): 844–7. doi:10.1136/jnnp.47.8.844. PMC 1027949. PMID 6236286.
- Peselow ED, Stanley M (1982). "Clinical trials of benzamides in psychiatry". Advances in Biochemical Psychopharmacology. 35: 163–94. PMID 6756060.
- Edwards JG, Alexander JR, Alexander MS, Gordon A, Zutchi T (December 1980). "Controlled trial of sulpiride in chronic schizophrenic patients". The British Journal of Psychiatry. 137 (6): 522–9. doi:10.1192/bjp.137.6.522. PMID 7011469.
- Levkovitz H, Abramovitch Y, Nitzan I (June 1994). "Leukocytosis related to the therapeutic dosage of sulpiride". Biological Psychiatry. 35 (12): 963. doi:10.1016/0006-3223(94)91244-0. PMID 8080896. S2CID 43471005.
- Melzer E, Knobel B (December 1987). "Severe cholestatic jaundice due to sulpiride". Israel Journal of Medical Sciences. 23 (12): 1259–60. PMID 3326861.
- Ohmoto K, Yamamoto S, Hirokawa M (December 1999). "Symptomatic primary biliary cirrhosis triggered by administration of sulpiride". The American Journal of Gastroenterology. 94 (12): 3660–1. PMID 10606349.
- Roth BL, Driscol J. "PDSP Ki Database". Psychoactive Drug Screening Program (PDSP). University of North Carolina at Chapel Hill and the United States National Institute of Mental Health. Retrieved 13 November 2020.
- Maitre M, Ratomponirina C, Gobaille S, Hodé Y, Hechler V (April 1994). "Displacement of [3H] gamma-hydroxybutyrate binding by benzamide neuroleptics and prochlorperazine but not by other antipsychotics". European Journal of Pharmacology. 256 (2): 211–4. doi:10.1016/0014-2999(94)90248-8. PMID 7914168.
- Ratomponirina C, Gobaille S, Hodé Y, Kemmel V, Maitre M (April 1998). "Sulpiride, but not haloperidol, up-regulates gamma-hydroxybutyrate receptors in vivo and in cultured cells". European Journal of Pharmacology. 346 (2–3): 331–7. doi:10.1016/S0014-2999(98)00068-5. PMID 9652377.
- Dong E, Nelson M, Grayson DR, Costa E, Guidotti A (September 2008). "Clozapine and sulpiride but not haloperidol or olanzapine activate brain DNA demethylation". Proceedings of the National Academy of Sciences of the United States of America. 105 (36): 13614–9. Bibcode:2008PNAS..10513614D. doi:10.1073/pnas.0805493105. PMC 2533238. PMID 18757738.
- Sneader W (31 October 2005). Drug Discovery: A History. John Wiley & Sons. pp. 205–. ISBN 978-0-470-01552-0.
- Sanger GJ (December 2009). "Translating 5-HT receptor pharmacology". Neurogastroenterology and Motility. 21 (12): 1235–8. doi:10.1111/j.1365-2982.2009.01425.x. PMID 19906028.
- Conard D (17 October 1991). "Synthélabo rachète les laboratoires Delagrange". Les Echos.
- "Laboratoires Delagrange". Bibliothèque nationale de France. Retrieved 24 August 2016.
- Meek T (24 May 2013). "A look back at Sanofi's merger with Synthélabo". PMLiVE.
- "Sulpiride". Drugs.com.
- Joint Formulary Committee. British National Formulary (online) London: BMJ Group and Pharmaceutical Press <http://www.medicinescomplete.com> [Accessed on 2 February 2020]
- Buvat J, Decroix-Blacker C, Legal F, Gasnault JP (January 1976). "[One thousand months of contraception with sulpiride]". Revue Française de Gynécologie et d'Obstétrique (in French). 71 (1): 53–61. PMID 959705.
- Payne MR, Howie PW, McNeilly AS, Cooper W, Marnie M, Kidd L (August 1985). "Sulpiride and the potentiation of progestogen only contraception". British Medical Journal. 291 (6495): 559–61. doi:10.1136/bmj.291.6495.559. PMC 1418199. PMID 2994800.